Since there are only so many interims scheduled for this trial (3), and designated alpha to be spent according to those and those alone, they cannot midway add another BSSR into the mix. Even with treatments assignments blinded it still spends alpha to view the whole group event data. It appears the next chance to halt won't be until the first interim. However, the closer we get to that, the higher the pps will likely climb, and the less willing (especially with other catalysts) investors will be to let go of their shares, imo.
It seems Linda was seriously on the fence whether to increase N or not ("we're thinking about it, it's a strategy point for us."). "If increase N to 360 or greater, either keep size at 240 or halt trial." Seems there was some talk of just keeping it at 240 instead of increasing to 348. But that most likely would have caused issues with regulators later, as it would have veered from protocol.
Market Data 
Markets 
AI
